MVA 85A -Protocol 008
A Phase I study evaluating the safety and immunogenicity of a new TB vaccine, MVA85A, in healthy volunteers with no evidence of infection with Mycobacterium tuberculosis
The objective of the study is to test safety and immunogenicity of the vaccine MVA85A.
The study methodology is open label, with 24 healthy adults, and 12 healthy BCG-vaccinated adolescents vaccinated and monitored for a year.
The study timeline is between 2005 and 2008.
Principal Investigator: Greg Hussey Co-PI: Helen McShane
Partners: Oxford University, Wellcome Trust